Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?

Key Takeaways Keytruda sales were $23.3B in the first nine months of 2025, up 8% Y/Y, anchoring MRK's revenue growth.MRK said Q3 Keytruda sales were softer due to channel movements, not weaker demand, with focus on Q4.MRK expects continued Keytruda growth from earlier-stage and metastatic use, aided by a new SC formulation.A meaningful portion of Merck’s (MRK) revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, Keytruda. The drug contributes over half of the company’s pha ...